Stephen Horrigan Email

Chief Scientific Officer . Iterion Therapeutics

Houston, TX

Location

s********@betacatpharma.com

Primary Email

https://www.linkedin.com/in/stephen-horrigan-b70821

How to contact Stephen Horrigan

Join and see Stephen's contact info for free!

s********@betacatpharma.com

Phone

254-383-****

Current Roles

Iterion Therapeutics

Employees:

Revenue:

$1.2M

About

Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/ -catenin signaling pathway, which is implicated in cell proliferation, differentiation, migration, apoptosis, immune evasion and stem cell renewal. Tegavivint has demonstrated pre-clinical in vivo efficacy in several cancer models, including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and multiple solid tumor types. The Company is enrolling a Phase I clinical study to evaluate safety and efficacy of Tegavivint in patients with desmoid tumors.

Iterion Therapeutics Address

2450 Holcombe Blvd
Houston, TX
United States